The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease.
糖尿病腎病患者中胰高血糖素樣肽-1受體激動劑的心血管和腎臟效應。
Cardiovasc Diabetol 2023-03-23
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease.
胰高血糖素治療在糖尿病和慢性腎臟病的機制和臨床應用。
Curr Opin Nephrol Hypertens 2023-09-17
Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?
GLP-1受體激動劑和SGLT-2抑制劑的腎保護作用-血液動力學是關鍵嗎?
Am J Physiol Cell Physiol 2023-07-11
Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist.
糖尿病患者合併慢性腎臟病的GLP-1受體激動劑管理:腎臟科醫師的處置方法。
Nefrologia (Engl Ed) 2024-01-30
Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease.
改變糖尿病護理:GLP1-RAs 如何影響糖尿病腎病的分子途徑。
Biomedicines 2024-03-30
Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes.
糖尿病患者使用胰高血糖素樣肽-1受體激動劑改善腎功能。
J Med Cases 2024-04-23
Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?
胰高血糖素樣肽受體-1 受體激動劑:2 型糖尿病和慢性腎病的新興第四支柱?
Med 2024-08-10